Proactive Investors - Run By Investors For Investors

Adial Pharmaceuticals making progress with alcohol use disorder drug

Adial Pharmaceuticals Inc (NASDAQ:ADIL) CEO William Stilley spoke with Proactive Investors at the MicroCap Conference in New York.

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of a therapeutic agent for the treatment of alcohol use disorder using its lead investigational new drug product, AD04, a selective serotonin-3 antagonist.

View full ADIL profile View Profile

Adial Pharmaceuticals Inc Timeline

Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use